Shepherd Kaplan Krochuk LLC Invests $143,000 in Checkpoint Therapeutics Inc (CKPT)

Shepherd Kaplan Krochuk LLC acquired a new stake in Checkpoint Therapeutics Inc (NASDAQ:CKPT) in the 3rd quarter, HoldingsChannel.com reports. The fund acquired 40,000 shares of the company’s stock, valued at approximately $143,000.

Several other institutional investors also recently made changes to their positions in the stock. Millennium Management LLC acquired a new position in Checkpoint Therapeutics in the first quarter valued at $331,000. Bainco International Investors acquired a new position in Checkpoint Therapeutics in the second quarter valued at $277,000. BlackRock Inc. acquired a new position in Checkpoint Therapeutics in the second quarter valued at $164,000. Finally, Renaissance Technologies LLC acquired a new position in Checkpoint Therapeutics in the third quarter valued at $284,000. 9.38% of the stock is owned by hedge funds and other institutional investors.

In related news, Director Lindsay A. Md Rosenwald acquired 100,000 shares of the company’s stock in a transaction dated Friday, November 9th. The shares were purchased at an average price of $2.29 per share, for a total transaction of $229,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 8.00% of the stock is currently owned by corporate insiders.

CKPT has been the topic of several recent analyst reports. HC Wainwright set a $11.00 target price on shares of Checkpoint Therapeutics and gave the company a “buy” rating in a report on Thursday, September 6th. Zacks Investment Research upgraded shares of Checkpoint Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a report on Monday, August 13th. Finally, ValuEngine upgraded shares of Checkpoint Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.

Shares of NASDAQ CKPT opened at $2.25 on Friday. Checkpoint Therapeutics Inc has a 1-year low of $1.89 and a 1-year high of $6.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its quarterly earnings data on Friday, November 2nd. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.06). Checkpoint Therapeutics had a negative net margin of 3,800.00% and a negative return on equity of 139.01%. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.26 million. As a group, sell-side analysts forecast that Checkpoint Therapeutics Inc will post -1.2 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This report was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.chaffeybreeze.com/2018/12/08/shepherd-kaplan-krochuk-llc-invests-143000-in-checkpoint-therapeutics-inc-ckpt.html.

Checkpoint Therapeutics Profile

Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC.

Featured Story: What are retained earnings?

Want to see what other hedge funds are holding CKPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Checkpoint Therapeutics Inc (NASDAQ:CKPT).

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply